SC 13G: CNS Pharmaceuticals, Inc.
Ticker: CNSP · Form: SC 13G · Filed: 2024-06-25T00:00:00.000Z
Sentiment: neutral
Topics: sc-13g
AI Summary
SC 13G filing by CNS Pharmaceuticals, Inc..
Risk Assessment
Risk Level: low
From the Filing
EDGAR Filing Documents for 0001626947-24-000004 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home Company Search Current Page Form SC 13G - Statement of Beneficial Ownership by Certain Investors: SEC Accession No. 0001626947-24-000004 Filing Date 2024-06-25 Accepted 2024-06-25 19:19:55 Documents 1 Document Format Files Seq Description Document Type Size 1 CNSP_RF1.txt SC 13G 9181 Complete submission text file 0001626947-24-000004.txt 10504 Mailing Address 54 DEEPDALE DR GREAT NECK NY 11021 Business Address Forster Robert (Filed by) CIK : 0001626947 (see all company filings) Type: SC 13G Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185 CNS Pharmaceuticals, Inc. (Subject) CIK : 0001729427 (see all company filings) EIN. : 822318545 | State of Incorp.: NV | Fiscal Year End: 1231 Type: SC 13G | Act: 34 | File No.: 005-93973 | Film No.: 241070261 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)